Study for the effects of semaglutide on glycemic control and quality of life in patients with type 2 diabetes
Phase 4
- Conditions
- Type 2 diabetes
- Registration Number
- JPRN-UMIN000042369
- Lead Sponsor
- Hokkaido University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 110
Inclusion Criteria
Not provided
Exclusion Criteria
1) patients with type 2 diabetes who were treated with GLP-1 receptor agonist other than liraglutide or dulaglutide 2) history of anaphylaxis of semaglutide 3) unstable retinopathy 4) severe hepatic dysfunction or renal dysfunction 5) severe ketosis, diabetic coma 6) severe infection, surgery, serious trauma 7) pregnancy 8) patients who are inadequate to enter this study due to the other reasons by physician's judgments
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The change in HbA1c from baseline at 24 weeks
- Secondary Outcome Measures
Name Time Method 1) The change in QOL scores 2) Adverse effects 3) The change in weight, abdominal circumference, blood pressure and pulse 4) The change in the other blood and urinary tests 5) The factors associated with improvement of HbA1c and secondary endpoints 6) Comparison of the changes between plan A and B when semaglutide demonstrates the superiority compared to both conventional GLP-1 receptor agonists
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms by which semaglutide improves glycemic control in type 2 diabetes compared to GLP-1 receptor agonists like liraglutide and dulaglutide?
How does semaglutide's efficacy in glycemic control compare to standard-of-care GLP-1 receptor agonists in Japanese patients with type 2 diabetes?
What biomarkers are associated with improved quality of life outcomes in type 2 diabetes patients treated with semaglutide versus other GLP-1 receptor agonists?
What are the potential adverse events associated with semaglutide in type 2 diabetes management and how do they compare to liraglutide and dulaglutide?
Are there any combination therapies involving semaglutide that show enhanced glycemic control in type 2 diabetes compared to monotherapy with GLP-1 receptor agonists?